SSSatoshi Sobajima

Satoshi Sobajima

*This is an algorithmically generated author record based on publicly available information.

Satoshi Sobajima has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Hideki Iwaguro

    Sobajima Clinic and Medical Institute for Regenerative Medicine, Osaka, Japan

    13 shared publications
  • Ryosuke Kuroda

    Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan

    10 shared publications
  • Takehiko Matsushita

    Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan

    9 shared publications
  • Tomoyuki Matsumoto

    Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan

    8 shared publications
  • Masanori Tsubosaka

    Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan

    6 shared publications
  • Tomoyuki Matsumoto

    Department of Orthopaedic Surgery Kobe University Graduate School of Medicine Kobe Japan

    3 shared publications

Latest Publications

  • Open Access

    Preclinical and early clinical safety of intra-articular spheroid adipose-derived stem cells for knee osteoarthritis: A translational study

    by Satoshi Sobajima, Yusuke Harada, Tae-Sun Kim, Osamu Kisaki, Kaito Otera, Hitoshi Yamauchi, Hiroshi Umemoto, Tomomi Makino, Emiko Nagao, Hideki Iwaguro

  • Open Access

    Factors affecting the therapeutic effects of multiple intra-articular injections of platelet-rich-plasma for knee osteoarthritis

    by Kohei Kamada, Takehiko Matsushita, Takahiro Yamashita, Tomoyuki Matsumoto, Hideki Iwaguro, Ryosuke Kuroda, Satoshi Sobajima


  • Open Access

    Factors Affecting the Therapeutic Effects of Multiple Intra-articular Injections of Platelet-Rich-Plasma for Knee Osteoarthritis

    by Kohei Kamada, Takehiko Matsushita, Takahiro Yamashita, Tomoyuki Matsumoto, Hideki Iwaguro, Ryosuke Kuroda, Satoshi Sobajima

    Background Platelet-rich-plasma (PRP) is rapidly spreading as a conservative treatment option for knee osteoarthritis (KOA), however, its therapeutic efficacy is controversial. This study aimed to investigate the factors affecting the therapeutic effect of intra-articular PRP therapy for KOA in patients who received multiple PRP injections (PRP-I).Methods This is a historical cohort study included 1057 knees of 701 patients who received PRP-I during KOA treatment from 2018 to 2020. The difference in visual analog scale (VAS) scores before and after PRP-I was defined as the amount of change in VAS (ΔVAS). Statistical analyses were performed using generalized linear mixed models with ΔVAS from the pre-treatment baseline as dependent variable and sex, age, number of PRP-I, and pre-treatment VAS as independent variables. Evaluations using the Kellgren-Lawrence (KL) classification were added.Results Age and VAS score before treatment and after three, four, and five PRP-I were significantly associated with ΔVAS score. According to KL grade, age was significantly associated with ΔVAS score in the KL grade 4 group. VAS score before treatment was significantly associated with ΔVAS score, regardless of KL grade. Three-time PRP-I were significantly associated with ΔVAS in the KL-grade 1 and 2 groups. For KL grade 4, two or more PRP-I were significantly associated with the high efficacy.Conclusions Age, pain before treatment, and number of injections were associated with pain reduction after intra-articular PRP-I for KOA treatment. Pain reduction can be expected after PRP-I when patients are younger or experience severe pain before treatment. Three-time PRP-I are recommended to reduce pain in early-stage KOA and more than three times in advanced-stage OA.Trial Registration: Retrospectively registration

  • Open Access

    Clinical use of autologous adipose-derived stromal vascular fraction cell injections for hip osteoarthritis

    by Yuma Onoi, Tomoyuki Matsumoto, Satoshi Sobajima, Masanori Tsubosaka, Shinya Hayashi, Takehiko Matsushita, Hideki Iwaguro, Ryosuke Kuroda


  • Open Access

    Clinical and Radiological Comparison of Single and Double Intra-articular Injection of Adipose-Derived Stromal Vascular Fraction for Knee Osteoarthritis

    by Masahiro Fujita, Tomoyuki Matsumoto, Satoshi Sobajima, Masanori Tsubosaka, Takehiko Matsushita, Hideki Iwaguro, Ryosuke Kuroda

    The aim of the article is to compare the clinical and radiological outcomes between single and double stromal vascular fraction (SVF) cell injections in patients with knee osteoarthritis (OA). We included 54 patients treated for varus knee OA with intra-articular SVF cell injection. They were divided into two groups: those who received one injection and those who received two. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, knee range of motion, and knee muscle force were assessed at baseline and 3, 6, 12, and 24 months after the first injection. The preoperative hip-knee-ankle (HKA) angle was evaluated using plain radiographs, and T2 mapping values were assessed. The total WOMAC score improved significantly in the single injection group from 3 to 24 months, but the total WOMAC score in the double injection group improved significantly at 24 months. The T2 mapping values in both the groups improved, with a significant difference at 12 months. The preoperative mean HKA angle and the correlation coefficients between the HKA angle and the total WOMAC score and between the HKA angle and the T2 mapping value of the medial femur were significant. In conclusion, double injections may provide more satisfactory treatment outcomes in patients with severe varus knee alignment. This clinical trial is registered in the Japanese Ministry of Health, Labour and Welfare (URL: https://saiseiiryo.mhlw.go.jp/published_plan/index/2 ) with the registration name “Cell transplantation therapy for osteoarthritis using autologous subcutaneous adipose tissue-derived regenerative (stem) cells (ADRCs),” and the registration number was “PB5160012.”


  • Open Access

    Author Correction: Local transplantation of adipose-derived stem cells has a significant therapeutic effect in a mouse model of rheumatoid arthritis

    by Hideki Ueyama, Tadashi Okano, Kumi Orita, Kenji Mamoto, Masaaki Ii, Satoshi Sobajima, Hideki Iwaguro, Hiroaki Nakamura

  • Open Access

    Attenuation of Knee Osteoarthritis Progression in Mice through Polarization of M2 Macrophages by Intra-Articular Transplantation of Non-Cultured Human Adipose-Derived Regenerative Cells

    by Kohei Kamada, Takehiko Matsushita, Takahiro Yamashita, Tomoyuki Matsumoto, Hideki Iwaguro, Satoshi Sobajima, Ryosuke Kuroda

    Adipose-derived regenerative cells (ADRCs) are non-cultured heterogeneous or mixed populations of cells obtained from adipose tissue by collagenase digestion. The injection of ADRCs have been tried clinically for the treatment of osteoarthritis (OA). The purpose of this study was to evaluate the effect of intra-articular transplantation of human ADRCs on OA progression in mice and the effect of ADRCs on macrophage polarization. In in vivo experiments, BALB/c-nu mice with knee OA received intra-articular transplantation of either phosphate buffered-saline or human ADRCs. OA progression was evaluated histologically and significantly attenuated in the ADRC group at both four and eight weeks postoperatively. The expression of OA-related proteins in the cartilage and macrophage-associated markers in the synovium were examined by immunohistochemistry. The numbers of MMP-13-, ADAMTS-5-, IL-1β-, IL-6- and iNOS-positive cells significantly decreased, and type II collagen- and CD206-positive cells were more frequently detected in the ADRC group compared with that in the control group. In vitro co-culture experiments showed that ADRCs induced macrophage polarization toward M2. The results of this study suggest that the intra-articular transplantation of human ADRCs could attenuate OA progression possibly by reducing catabolic factors in chondrocytes and modulating macrophage polarization.


  • Open Access

    Comparison of Clinical and Imaging Outcomes of Different Doses of Adipose-Derived Stromal Vascular Fraction Cell Treatment for Knee Osteoarthritis

    by Masanori Tsubosaka, Tomoyuki Matsumoto, Satoshi Sobajima, Takehiko Matsushita, Hideki Iwaguro, Ryosuke Kuroda

    Background: Favorable clinical outcomes of the intra-articular injection of adipose-derived stromal vascular fraction (SVF) cells for knee osteoarthritis (OA) have been reported. This study aimed to compare the short-term clinical and imaging outcomes of different doses of SVF cells for knee OA treatment.Methods: This study included 60 patients with knee OA who underwent intra-articular injection of SVF cells. The follow-up period was at least 12 months. The envelope method was used to prospectively quasi-randomized the patients to undergo treatment with different doses of SVF cells. Thirty patients received an intra-articular injection of 2.5×107 SVF cells (low-dose group), and the remaining 30 patients received an intra-articular injection of 5.0×107 SVF cells (high-dose group). Clinical evaluations were performed for range of motion, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), visual analog scale (VAS) for pain, and the Knee injury and Osteoarthritis Outcome Score (KOOS). Imaging evaluations, which included the hip-knee-ankle angle and magnetic resonance imaging Osteoarthritis Knee Score (MOAKS) features (bone marrow lesions, cartilage defects, osteophytes, Hoffa’s synovitis, and effusion synovitis), were also performed. All clinical and imaging evaluations were performed preoperatively and 12 months postoperatively and compared between the groups.Results: No significant differences in demographic data were found between the two groups. The knee extension angle at 12 months postoperatively was significantly higher than the preoperative angle in both groups. The total WOMAC and VAS scores at 12 months postoperatively were significantly more favorable than preoperative scores in both groups. The bone marrow lesions and Hoffa’s synovitis and effusion synovitis improved approximately 30-40% from baseline to 12 months postoperatively in both groups. However, there were no significant differences in the preoperative and postoperative results of any clinical or imaging evaluation between the two groups.Conclusions: The short-term clinical and imaging outcomes of intra-articular injection of SVF cells for knee OA were excellent, regardless of whether a low- or high-dose was administered. Intra-articular injection of SVF cells for knee OA is an innovative approach.

  • Open Access

    Comparison of Clinical and Imaging Outcomes of Different Doses of Adipose-Derived Stromal Vascular Fraction Cell Treatment for Knee Osteoarthritis

    by Masanori Tsubosaka, Tomoyuki Matsumoto, Satoshi Sobajima, Takehiko Matsushita, Hideki Iwaguro, Ryosuke Kuroda

    Favorable clinical outcomes of intra-articular injection of adipose-derived stromal vascular fraction (SVF) cells for knee osteoarthritis (OA) have been reported, but the effects of different doses of SVF cells have not been examined. This study aimed to compare the short-term clinical and imaging outcomes of different doses of SVF cells for knee OA treatment. This study included 60 patients with knee OA who underwent intra-articular injection of SVF cells. The follow-up period was at least 12 months. Thirty patients received an intra-articular injection of 2.5×107 SVF cells (low-dose group), and the remaining 30 patients received an intra-articular injection of 5.0×107 SVF cells (high-dose group). Clinical evaluations were performed for the Knee injury and Osteoarthritis Outcome Score (KOOS). Imaging evaluations, including the magnetic resonance imaging Osteoarthritis Knee Score (MOAKS) features (bone marrow lesions, cartilage defects, osteophytes, Hoffa’s synovitis, and effusion synovitis), were also performed. All clinical and imaging evaluations were performed preoperatively and 12 months postoperatively and compared between the groups. In demographic data, no significant differences were found between the two groups. The total score of KOOS at 12 months postoperatively was significantly more favorable than the preoperative score in the high-dose groups. Pain and symptoms subscale scores of KOOS at 12 months postoperatively were significantly better in the high-dose group than in the low-dose group. The bone marrow lesions, Hoffa’s synovitis, and effusion synovitis improved approximately 30–40% at 12 months postoperatively compared to baseline in both groups. However, there were no significant differences in imaging evaluations between the two groups. In conclusion, the pain and symptoms subscale scores of KOOS from baseline to 12 months postoperatively improved better in the high-dose group than in the low-dose group. Our findings suggest that intra-articular injection of SVF cells for knee OA is an innovative approach.